TocilizumabV1, Main, Exploration, bibRecord, 001887

Biologics for idiopathic inflammatory myopathies.

Identifieur interne : 001887 ( Main/Exploration ); précédent : 001886; suivant : 001888

Biologics for idiopathic inflammatory myopathies.

Auteurs : Siamak Moghadam-Kia [États-Unis] ; Rohit Aggarwal ; Chester V. Oddis

Source :

Current opinion in rheumatology [ 1531-6963 ] ; 2017.

RBID : pubmed:28817464

Descripteurs français

KwdFr :
- Abatacept (usage thérapeutique), Humains, Immunosuppresseurs (usage thérapeutique), Myosite (immunologie), Myosite (traitement médicamenteux), Produits biologiques (usage thérapeutique), Rituximab (usage thérapeutique), Résultat thérapeutique.
MESH :
- immunologie : Myosite.
- traitement médicamenteux : Myosite.
- usage thérapeutique : Abatacept, Immunosuppresseurs, Produits biologiques, Rituximab.
- Humains, Résultat thérapeutique.

English descriptors

KwdEn :
- Abatacept (therapeutic use), Biological Products (therapeutic use), Humans, Immunosuppressive Agents (therapeutic use), Myositis (drug therapy), Myositis (immunology), Rituximab (therapeutic use), Treatment Outcome.
MESH :
- chemical , therapeutic use : Abatacept, Biological Products, Immunosuppressive Agents, Rituximab.
- drug therapy : Myositis.
- immunology : Myositis.
- Humans, Treatment Outcome.

Abstract

As treatment of refractory cases of idiopathic inflammatory myopathies (IIMs) has been challenging, there is growing interest in assessing novel biologics that target various pathways implicated in the pathogenesis of IIM.

DOI: 10.1097/BOR.0000000000000432
PubMed: 28817464

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Biologics for idiopathic inflammatory myopathies.</title>
<author><name sortKey="Moghadam Kia, Siamak" sort="Moghadam Kia, Siamak" uniqKey="Moghadam Kia S" first="Siamak" last="Moghadam-Kia">Siamak Moghadam-Kia</name>
<affiliation wicri:level="2"><nlm:affiliation>aDivision of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Myositis Center bVA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>aDivision of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Myositis Center bVA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Aggarwal, Rohit" sort="Aggarwal, Rohit" uniqKey="Aggarwal R" first="Rohit" last="Aggarwal">Rohit Aggarwal</name>
</author>
<author><name sortKey="Oddis, Chester V" sort="Oddis, Chester V" uniqKey="Oddis C" first="Chester V" last="Oddis">Chester V. Oddis</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28817464</idno>
<idno type="pmid">28817464</idno>
<idno type="doi">10.1097/BOR.0000000000000432</idno>
<idno type="wicri:Area/PubMed/Corpus">000A50</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A50</idno>
<idno type="wicri:Area/PubMed/Curation">000A50</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A50</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000C16</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000C16</idno>
<idno type="wicri:Area/Ncbi/Merge">001700</idno>
<idno type="wicri:Area/Ncbi/Curation">001700</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001700</idno>
<idno type="wicri:Area/Main/Merge">001886</idno>
<idno type="wicri:Area/Main/Curation">001887</idno>
<idno type="wicri:Area/Main/Exploration">001887</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Biologics for idiopathic inflammatory myopathies.</title>
<author><name sortKey="Moghadam Kia, Siamak" sort="Moghadam Kia, Siamak" uniqKey="Moghadam Kia S" first="Siamak" last="Moghadam-Kia">Siamak Moghadam-Kia</name>
<affiliation wicri:level="2"><nlm:affiliation>aDivision of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Myositis Center bVA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>aDivision of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Myositis Center bVA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Aggarwal, Rohit" sort="Aggarwal, Rohit" uniqKey="Aggarwal R" first="Rohit" last="Aggarwal">Rohit Aggarwal</name>
</author>
<author><name sortKey="Oddis, Chester V" sort="Oddis, Chester V" uniqKey="Oddis C" first="Chester V" last="Oddis">Chester V. Oddis</name>
</author>
</analytic>
<series><title level="j">Current opinion in rheumatology</title>
<idno type="eISSN">1531-6963</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abatacept (therapeutic use)</term>
<term>Biological Products (therapeutic use)</term>
<term>Humans</term>
<term>Immunosuppressive Agents (therapeutic use)</term>
<term>Myositis (drug therapy)</term>
<term>Myositis (immunology)</term>
<term>Rituximab (therapeutic use)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Abatacept (usage thérapeutique)</term>
<term>Humains</term>
<term>Immunosuppresseurs (usage thérapeutique)</term>
<term>Myosite (immunologie)</term>
<term>Myosite (traitement médicamenteux)</term>
<term>Produits biologiques (usage thérapeutique)</term>
<term>Rituximab (usage thérapeutique)</term>
<term>Résultat thérapeutique</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Abatacept</term>
<term>Biological Products</term>
<term>Immunosuppressive Agents</term>
<term>Rituximab</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Myositis</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Myosite</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Myositis</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Myosite</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Abatacept</term>
<term>Immunosuppresseurs</term>
<term>Produits biologiques</term>
<term>Rituximab</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Humains</term>
<term>Résultat thérapeutique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">As treatment of refractory cases of idiopathic inflammatory myopathies (IIMs) has been challenging, there is growing interest in assessing novel biologics that target various pathways implicated in the pathogenesis of IIM.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Pennsylvanie</li>
</region>
</list>
<tree><noCountry><name sortKey="Aggarwal, Rohit" sort="Aggarwal, Rohit" uniqKey="Aggarwal R" first="Rohit" last="Aggarwal">Rohit Aggarwal</name>
<name sortKey="Oddis, Chester V" sort="Oddis, Chester V" uniqKey="Oddis C" first="Chester V" last="Oddis">Chester V. Oddis</name>
</noCountry>
<country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Moghadam Kia, Siamak" sort="Moghadam Kia, Siamak" uniqKey="Moghadam Kia S" first="Siamak" last="Moghadam-Kia">Siamak Moghadam-Kia</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001887 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001887 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:28817464
   |texte=   Biologics for idiopathic inflammatory myopathies.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:28817464" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a TocilizumabV1

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021

Serveur d'exploration Tocilizumab

Biologics for idiopathic inflammatory myopathies.

Biologics for idiopathic inflammatory myopathies.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration Tocilizumab
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.